Optune Lua™ is the new FDA approved name for NovoTTF-100L™. All NovoTTF-100L materials will be updated shortly with the new name, Optune Lua. Thank you for your patience while we make these updates. Read the Press Release

Read the Press Release
Indicated for the treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM)

Optune Lua is the first FDA-approved treatment for MPM in over 15 years1-4

Optune Lua and pemetrexed + cisplatin/carboplatin may help your patients with MPM live longer with no added chemotherapy-related side effects1

18.2 months - Primary endpoint - Median overall survival (OS) - (95% CI 12.1-25.8) across all patients treated with Optune Lua™ and pemetrexed + cisplatin/carboplatin

Optune Lua approval was based on the STELLAR trial: a phase II, prospective, pivotal, single-arm trial designed to study the safety and efficacy of Optune Lua and pemetrexed + cisplatin/carboplatin first-line in patients with unresectable, locally advanced or metastatic, MPM.2

No systemic AEs were considered to be related to the use of Optune Lua1

  • The only AE attributed to the use of Optune Lua is the known skin irritation seen in 71% of patients in this study (66% mild to moderate and 5% severe)
Learn more about Optune Lua™

Optune Lua is designed to fit 
into your patients' daily lives

See how


Novocure® offers an award-winning support program

nCompassTM offers customized support based on patient and caregiver needs


Learn more about nCompass™


Helpful resources for you
and your patients

Explore resources

References: 1. Optune Lua . Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2019. 2. FDA Approves the NovoTTF-100L System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [press release]. St. Helier, Jersey: Business Wire; May 23, 2019. 3. Hazarika M, White RM, Johnson JR, et al. FDA drug approval summaries: pemetrexed (Alimta®). The Oncologist. 2004;9(5):482-488. 4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644.

Next: HDE approval for unresectable MPM
Back to top
Indications For Use
jump to isi

The Optune Lua System is indicated for the treatment of adult patients with unresect…